Comparative Pharmacology
Head-to-head clinical analysis: TOFACITINIB CITRATE versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOFACITINIB CITRATE versus XELJANZ.
TOFACITINIB CITRATE vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), thereby modulating cytokine signaling and downregulating immune and inflammatory responses.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
5 mg orally twice daily for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; 10 mg orally twice daily for ulcerative colitis induction (8 weeks maximum).
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2–4 hours) in patients with normal renal function, allowing twice-daily dosing. Half-life is prolonged in moderate to severe renal impairment (up to 5–8 hours) and in hepatic impairment.
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Approximately 70% of the dose is eliminated by hepatic metabolism, with about 30% excreted unchanged in urine and <10% in feces. Renal excretion accounts for ~30% of total clearance.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category D/X
Category C
JAK Inhibitor
JAK Inhibitor